Dr. Kessler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd Nw
Washington, DC 20007Phone+1 202-444-2223
Summary
- Dr. Craig Kessler is a hematologist/oncologist in Washington, DC and is affiliated with MedStar Georgetown University Hospital. He received his medical degree from Tulane University School of Medicine and has been in practice 44 years. He specializes in hematologic oncology and is experienced in hematologic oncology, thrombotic disorders, bleeding disorders, general / benign hematology, and myeloproliferative neoplasms.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1977 - 1978
- Johns Hopkins UniversityResidency, Internal Medicine, 1976 - 1977
- Ochsner Clinic FoundationResidency, Internal Medicine, 1973 - 1976
- Tulane University School of MedicineClass of 1973
Certifications & Licensure
- DC State Medical License 1981 - 2027
- LA State Medical License 1973 - 2008
- VA State Medical License 1987 - 2004
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A Start of enrollment: 2006 Apr 01
- IGIV Study for Chronic ITP Patients Ages 3-70 Start of enrollment: 2008 May 01
- Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.Jacqueline N Poston, Cassandra Bryan, Annette von Drygalski, Kadhim Al Banaa, Jenny Y Zhou
Blood Advances. 2024-11-26 - Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcom...Neil A Goldenberg, Sam Schulman, John M Kittelson, Thomas C Abshire, James F Casella
Journal of Thrombosis and Haemostasis. 2024-10-24 - Risk of myeloproliferative neoplasms among U.S. Veterans from Korean, Vietnam, and Persian Gulf War eras.Andrew Tiu, Zoe McKinnell, Shanshan Liu, Puneet Gill, Martha Antonio
American Journal of Hematology. 2024-10-01
Journal Articles
- Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized AnticoagulationAlex C Spyropoulos, Craig M Kessler, Bhavi Pandya, Seminars in Thrombosis and Hemostasis
Abstracts/Posters
- Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...Craig M. Kessler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Protecting Our Vulnerable, Medically Ill Patients From Venous Thromboembolism60th American Society of Hematology Annual Meeting - 11/30/2018
- Ninth Annual Hematology Conference: An Update on Selected ASH TopicsThe University of Tennessee Graduate School of Medicine, Knoxville, Tennessee - 1/19/2013
Authored Content
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsJuly 2017
Press Mentions
- FDA Approves New Treatment for People with Hemophilia BAugust 20th, 2024
- Local Hospitals Begin Treating Coronavirus Patients with Blood from SurvivorsApril 22nd, 2020
- Sangamo Announces Treatment of First Patient in Clinical Trial of in Vivo Genome Editing Therapy for Hemophilia BDecember 20th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: